Invest now
Eris Lifesciences share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹1,320.50(1.28%)September 4, 2026 15:28:43 PM IST
- NSE
- BSE
- Vol : 167.06 K (NSE + BSE)Last 20 day avg : 128.83 K
Eris Lifesciences is trading 1.28% upper at Rs 1,320.50 as compared to its last closing price. Eris Lifesciences has been trading in the price range of 1,332.05 & 1,293.50. Eris Lifesciences has given -13.42% in this year & -0.66% in the last 5 days. Eris Lifesciences has TTM P/E ratio 30.62 as compared to the sector P/E of 37.27.There are 11 analysts who have initiated coverage on Eris Lifesciences. There are 5 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 142.39 Crores in its last quarter.Listed peers of Eris Lifesciences include Sun Pharmaceutical Industries (-0.26%), Divi's Laboratories (-1.57%), Torrent Pharmaceuticals (-1.52%).The Mutual Fund holding in Eris Lifesciences was at 18.88% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Eris Lifesciences was at 5.76% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 07 Sep 2026, 08:03 AM IST
- BetaLow volatility0.73Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.60The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.55Annual dividends as a percentage of the stock price.
- PEG RatioIndicates Fair Valuation1.61The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Eris Lifesciences News
Eris Lifesciences Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,899.00 | -0.26 | 4,55,622.97 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,100.00 | -1.57 | 2,41,576.41 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,850.00 | -1.52 | 1,84,471.81 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,385.00 | -0.29 | 1,11,887.66 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,121.00 | -1.23 | 1,11,820.17 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allEris Lifesciences Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-29 | Quarterly Results |
| 2026-05-20 | Audited Results & Interim Dividend |
| 2026-02-13 | Quarterly Results |
| 2025-11-24 | Preferential issue of shares |
| 2025-11-12 | Quarterly Results |
About the company Eris Lifesciences
- IndustryBiotechnology & Drugs
- ISININE406M01024
- BSE Code540596
- NSE CodeERIS
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
Eris Lifesciences Share Price FAQs
Eris Lifesciences is trading at 1320.50 as on Fri Sep 04 2026 09:58:43. This is 1.28% upper as compared to its previous closing price of 1303.85.
The market capitalization of Eris Lifesciences is 18361.89 Cr as on Fri Sep 04 2026 09:58:43.
The average broker rating on Eris Lifesciences is Strong Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 5 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Eris Lifesciences is 1805.20 whereas the 52 wk low is 1237.90
Eris Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 30.62
- Sector P/E: 37.27
- Dividend Yield: 0.55%
- D/E ratio: -
Eris Lifesciences reported a net profit of 619.52 Cr in 2026.
The Mutual Fund Shareholding was 18.88% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Eris Lifesciences QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.